The risks of BSIs vary according to the type of parental nutrition provided. The safest approach, consisting of ready-to-use three-chamber bag (MCB), was also shown to be essentially cost neutral.
For oral medications with restrictions, understanding physician and patient knowledge gaps is critical to ensuring patients receive appropriate medication directions.
BETHESDA, MD, USA. April 2, 2014 -- Pharmerit International is pleased to announce the recent publication of a research paper conducted by Pharmerit International authors Caitlyn Solem
A systematic literature review on the prevalence, measurement methods, consequences and risk factors for non-adherence to BCR-ABL inhibitors and adherence-enhancing interventions.
Clinical Therapeutics published study on systolic blood pressure, in which Phamerit made a significant contribution.
The Journal of Medical Decision Making will feature a Pharmerit study on modelling individual components of a combined endpoint.
We have enjoyed meeting you at the 16th European ISPOR conference in Dublin, November 2013.
Journal of Medical Economics (September 2013) publishes Pharmerit´s cost-effectiveness study on adjuvant therapy to prevent gastrointestinal stromal tumour recurrence.
England and Wales’ National Institute for Health and Care Excellence (NICE) has positively
reviewed the pharmaco-economic submission by the manufacturer of ocriplasmin (Jetrea®).
Publication on alpha-blocker and anti-muscarinic combination treatment has been
positively reviewed by the NHS Centre for Reviews and Dissemination (CRD).